Uncover primary receptors and off-targets

Retrogenix’s cell microarray technology is the most powerful solution for identifying the specific human plasma membrane proteins that are targeted by antibodies, proteins, small molecules, viruses and other ligands.  We discover high quality, exploitable drug targets and mechanisms of action for our global pharmaceutical clients as well as screening for potential off-targets to inform lead selection and assist with safety assessment.

  • High success rates
  • High specificity
  • Low false positive rates
  • Rapid turnaround (6-8 weeks)

Our unrivalled technology identifies interactions with cell surface receptors by screening test ligands for binding against over 4,500 full length proteins that are individually over-expressed in human cells.  This physiologically-relevant system, coupled with our broad coverage of the plasma membrane proteome, allows even low affinity interactions to be detected with a high degree of sensitivity and specificity.

Retrogenix works with small biotechs and leading academic groups through to major pharmaceutical companies, currently helping fourteen of the world’s top fifteen drug developers to bring new therapeutics to market faster.

Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
We’ve developed a terrific working relationship with the team at Retrogenix and intend to utilize their microarray technology as a standard screen for future targets. Jim and Jo have become trusted collaborators and we appreciate their flexibility and willingness to work with us through some challenging issues. The quality and timeliness of the data and reports are first rate. We’ve come to rely on their results as a dependable means to confirm results from traditional crossreactivity studies and to identify additional potential unexpected interactions.
Amy Bourdeau, ‎Senior Preclinical Development Coordinator, Bluebird bio